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Mechanical stretch induces podocyte hypertrophy in vitro.
Background. Increased intraglomerular pressure is a fi-
nal pathway toward glomerulosclerosis in systemic hyperten-
sion, diabetes, and focal segmental glomerulosclerosis (FSGS).
Increased intraglomerular pressure causes stress-tension, or
stretch, on resident glomerular cells. However, the effects of
stretch on podocyte growth, and the mechanisms that underlie
this, have not been elucidated.
Methods. To test the hypothesis that stretch alters podocyte
growth, cultured mouse podocytes were exposed to cyclic me-
chanical stretch created by vacuum; control cells were grown
under similar conditions, but not exposed to stretch. Prolifer-
ation (cell cycle phases) and hypertrophy (forward light scat-
ter) were measured in stretched and control podocytes by flow
cytometry. The role of the cyclin-dependent kinase (CDK) in-
hibitors, p21 and p27, was examined by stretching podocytes
isolated from p21 and p27 knockout (−/−) mice, and the role of
specific signaling pathways was assessed by Western blot anal-
ysis and blocking studies.
Results. Our results showed that stretch reduced cell cycle
progression in wild-type and single p27−/− podocytes and in-
duced hypertrophy in these cells in all phases of the cell cycle
at 24, 48, and 72 hours. In contrast, stretch did not induce hy-
pertrophy in single p21−/− and double p21/p27−/− podocytes.
Stretch-induced hypertrophy required cell cycle entry, and was
prevented by specifically blocking extracellular signal-regulated
kinase 1/2 (Erk1/2) or Akt. Although stretch increased p38 acti-
vation, inhibition of this pathway had no effect on hypertrophy.
Conclusion. Mechanical stretch induces hypertrophy in
podocytes in vitro in all phases of the cell cycle. This effect is
cell cycle dependent, and requires p21, Erk1/2, and Akt. Stretch
may play a role in podocyte injury when intraglomerular pres-
sure is increased.
Podocytes, also called visceral glomerular epithelial
cells, are terminally differentiated cells that line the
outer surface of the glomerular basement membrane
1See Editorial by Kriz and Endlich, p. 373.
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[1]. Podocytes prevent protein leakage into the urinary
space, and also provide important tensile strength to the
glomerular capillaries, by opposing the hydrostatic pres-
sure from within [2]. Podocytes are injured in a variety of
immune and nonimmune forms of injury. The responses
to podocyte injury include the release of oxidants and
proteases, increase in synthesis of growth factors and cy-
tokines, and activation of specific signaling pathways [3].
The consequences of podocyte injury include cell cycle
entry with or without proliferation, detachment, accumu-
lation of extracellular matrix proteins, and hypertrophy
[4, 5].
In contrast to glomerular endothelial and mesangial
cells, podocytes do not typically proliferate. Studies have
shown that following podocyte loss, the inability of
podocytes to proliferate contributes to the development
of glomerulosclerosis [6]. Consequently, in order to cover
the denuded glomerular basement membrane, podocytes
increase in size due to hypertrophy. Although this is
initially compensatory, podocyte hypertrophy is likely
maladaptive, and contributes to glomerulosclerosis. Cell
growth (proliferation and hypertrophy) has been shown
to be cell cycle dependent [7, 8]. Progression through the
cell cycle requires that cyclin-dependent kinases (CDKs)
are activated by partner cyclins [9]. However, cyclin-CDK
complexes are inhibited by CDK inhibitors, which in-
clude p21Cip1,Waf1 (p21), p27Kip1 (p27), and p57Kip2 (p57)
[10]. Cell growth is also dependent on cell attachment
and the presence of mitogens [11], which signal through
specific signaling pathways, such as mitogen-activated
protein kinase (MAPK) and Akt pathways [12]. Extra-
cellular signal-regulated kinase 1/2 (Erk1/2) and Akt are
activated by mitogens, and are proproliferative [13, 14].
p38 is activated by environmental stress [15].
Studies have shown that increased intraglomerular
capillary pressure causes progressive glomerulosclerosis
in diabetic and nondiabetic glomerular disease, and this
is associated with podocyte hypertrophy [16]. However,
the mechanisms causing podocyte hypertrophy are not
known. In order to determine if increased intraglomeru-
lar capillary pressure causes podocyte hypertrophy, and
to determine the mechanisms underlying this effect, we
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exposed cultured mouse podocytes to cyclic mechanical
stretch. Our results show that stress-tension–induced in-
jury generated by mechanical stretch induces podocyte
hypertrophy, and this requires the presence of the CDK
inhibitor p21. Stretch also reduces podocyte prolifera-
tion, due to a decrease in Erk1/2 and Akt.
METHODS
Cell culture
Primary cultures of mouse podocytes were derived
from single p21, single p27, double p21/p27 null (−/−) and
wild-type (+/+) C57/bl6 mice by differential glomeru-
lar sieving as previously described [17]. Briefly, follow-
ing removal of the kidney capsule, the cortex was finely
cut using a scalpel, and gently passed through a sieve
with a pore size of 107 lm, placed over a sieve with a
pore size of 65 lm. Isolated glomeruli were then passed
through a 107 lm sieve a second time, and collected
on a sieve with a pore size of 53 lm. Following cen-
trifugation, glomeruli were seeded onto vitrogen-coated
10 cm culture plates (Collagen Biomaterials, Palo Alto,
CA, USA) in a media consisting of equal parts condi-
tioned 3T3 media and K1 media (2% NuSerum and 0.5%
ITS-Premix) (Becton Dickinson, Bedford, MA, USA),
penicillin (100 U/mL), streptomycin (100 lg/mL), and
glutamine (2 mmol/L) (all from Irvine Scientific, Santa
Ana, CA, USA). Nonattached glomeruli were removed
by washing after 5 days, at which time adherent glomeruli
were transferred to 24-well collagen I–coated plates, us-
ing cloning rings. Podocytes were characterized by im-
munofluorescense for podocin (gift of Peter Mundel,
Albert Einstein College of Medicine, New York, NY,
USA) and nephrin (gift of Dr. Harry Holthofer; Univer-
sity of Helsinki, Helskinki, Finland), and the absence of
alpha-smooth muscle actin (a-SMA) staining (marker for
mesangial cells) and factor VIII immunostaining (marker
for endothelial cells). Although all mice were identified
by genotyping prior to sacrifice, levels of the CDK in-
hibitors p21 and p27 were also measured in podocytes in
vitro by Western blot analysis (see below).
Experimental design
In order to determine the effect of stretch on podocyte
proliferation, mouse podocytes were plated onto 6-well,
flexible-bottom plates coated with bovine type I collagen
(Flexcell International Corp., Hillsborough, NC, USA)
at a confluency of about 10% to 20%. Cells were al-
lowed to attach overnight in media containing 5% serum.
Podocytes were then synchronized into quiescence by
growing cells in medium with 0.5% serum for 72 hours,
which prevented apoptosis. To test the hypothesis that
stretch induced podocyte hypertrophy, serum-free media
was replaced by media containing 5% serum (used as
a source of growth factors). To induce stretch-tension,
podocytes were exposed to continuous cycles of me-
chanical stretch/relaxation using the Flexercell Strain
Unit 2000 (Flexcell International Corp.) according to the
manufacturer’s directions, and as we have previously de-
scribed [17]. To determine the optimal experimental con-
ditions, podocytes were exposed to either continuous
or cyclic mechanical stretch where tensions generated
ranged from 5% to 20% biaxial surface elongation.
Based on our preliminary data, we utilized stretch cy-
cles of 0.5 second of stretch and 0.5 second of relaxation
for a total of 60 cycles per minute in the current study.
The vacuum pressure was –30.92 kPa, which induced an
average of 5% circumferential radius elongation in the
surface of the culture plates. Control cells were grown un-
der identical conditions, but were not exposed to stretch
(i.e., static conditions). Studies of cell growth (prolifera-
tion and hypertrophy) were performed in stretched and
control cells at 24 hours, 48 hours, and 72 hours after the
initiation of stretch (see below). To determine the role
of mitogens in stretch-induced hypertrophy, podocytes
grown in 0.5% of serum were exposed to stretch in se-
lected experiments. All experiments described were per-
formed a minimum of three times.
Measuring hypertrophy and proliferation
Cell size was used as a measure of hypertrophy, and
this was assessed by flow cytometry. Stretched and control
(nonstretched) podocytes were harvested by trypsiniza-
tion, centrifuged, washed twice with phosphate-buffered
saline (PBS), and resuspended in 70% ethanol, and
stored at −20◦C until analysis. Upon thawing, podocytes
were stained with propium iodide (50 lg/mL) containing
RNAse A (30 U/mL) (both from Sigma Chemical Co., St.
Louis, MO, USA), and cell size was measured by forward
light scatter using flow cytometer (Becton Dickinson Im-
munocytometry Systems, San Jose, CA, USA). Cell size
was assessed in each phase of the cell cycle. Forward light
scatter measures cell diameter, and this measure was used
to calculate cell volume for cells in each phase of the cell
cycle, using the equation V = 4/3 × r3 × p . Cell volume
is reported in this study.
Proliferation was also determined by measuring the
percentage of cells in each phase of the cell cycle at
24 hours in control and stretched cells. All experiments
were repeated a minimum of four times. The role of Erk,
Akt, and p38 in stretch-induced hypertrophy was deter-
mined by stretching podocytes in 0.5% serum and adding
specific inhibitors to the media 30 minutes before the ini-
tiation of stretch as follows: SB203580 for p38 (20 lmol/L)
(A.G. Scientific, San Diego, CA, USA), Ly294002 for
phosphoinositide 3 kinase (PI3K) an upstream activator
of Akt (50 lmol/L) (Cell Signaling Technology, Beverly,
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MA, USA), and PD98059 for Erk (50 lmol/L) (Sigma
Chemical Co.).
Western blot analysis
Western blot analysis was used to measure protein lev-
els of specific cell cycle proteins and signaling pathways
in stretched and control (nonstretched) cells. Protein was
extracted at early (5 minutes, 15 minutes, 30 minutes,
and 1 hour), and late (6 hours, 12 hours, 24 hours,
48 hours, and 72 hours) time points following the initi-
ation of stretch using trypsin/collagenase digestion, and
lysis in “TG buffer“ containing 1% Triton, 10% glycerol,
20 mmol/L Hepes, and 100 mmol/L NaCl with a mixture
of protease (Complete Protease Inhibitor) (Boehringer
Mannheim Biochemica, Mannheim, Germany) and phos-
phatase inhibitors [1 mmol/L ethyleneglycol tetraacetic
acetate (EGTA), 2.5 mmol/L sodium-pyrophosphate,
1 mmol/L b-glycerophosphate, and 1 mmol/L sodium-
orthovandate] as previously described [18]. Total protein
concentration was measured by the BCA Protein As-
say Kit (Pierce, Rockford, IL, USA) according to the
manufacturer’s instructions. For Western blot analysis,
reducing buffer was added to 10 to 20 lg of protein ex-
tract, boiled for 5 minutes and samples were separated on
7.5 or 15% polyacrylamide gel electrophoresis (PAGE)
precast gels (BMA, Rockland, ME, USA). Protein was
transferred for 1 hour onto PolyScreen polyvinlydine
difluoride (PVDF) Transfer Membranes (NEN Life Sci-
ence Products, Boston, MA, USA); nonspecific back-
ground was blocked by washing with 5% nonfat dried
milk in Tris-buffered saline with 0.1% Tween (TBST)
buffer for 30 minutes, followed by incubation with the
primary antibody overnight.
The following primary antibodies were used: p21 (1:200
dilution) (PharMingen, San Diego, CA, USA), Erk1/
2-P (Thr202/Tyr204) (1:1000 dilution), Raf-P (Ser259)
(1:1000 dilution), Mek1/2-P (Ser217/221) (1:1000 dilu-
tion), p90-P (Ser381) (1:1000 dilution), p38-P (Thr180/
Tyr182) (1:1000 dilution), Akt-P-S (Ser473) (1:1000 dilu-
tion), Akt-P-T (Thr308) (1:1000 dilution), and glycogen
synthase kinase (GSK)-3b-P (Ser9) (1:500 dilution) (all
from Cell Signaling Technology, Beverly, MA, USA). All
antibodies are specific for the phosphorylated kinases.
After washing with TBST buffer, membranes were
incubated with an alkaline phosphatase-conjugated
secondary antibody for 1 hour at room temperature. Sec-
ondary antibodies used were antimouse IgG (H + L)
alkaline phosphatase-conjugated and antirabbit IgG (Fc)
alkaline phosphatase-conjugated (all 1:2000 dilution)
(Promega, Madison, WI, USA). Protein bands were
made visible with the chromagen 5-bromo-4-chloro-3-
indolylphosphate/nitro blue tetrazolium (Sigma Chem-
ical Co.). To ensure that the results obtained by Western
blot analysis were not due to unequal protein loading or
protein transfer, we routinely performed double-staining
with an antibody to actin (1:4000 dilution) (Boehringer
Mannheim) or alpha/beta tubulin (1:2000 dilution) (Neo-
markers, Fremont, CA, USA). Total protein was also used
as a loading control for the phosphorylated form of spe-
cific signaling proteins (Akt, Erk, GSK, p38).
Statistical analysis
Results in this study were expressed as mean ± SD.
Statistical analsysis was performed by the Student t test.
RESULTS
Mechanical stretch does not induce hypertrophy in the
G0/G1 phase in the absence of p21
Hypertrophy was measured in stretched and control
(nonstretched) podocytes by assessing cell size (vol-
ume) utilizing forward light scatter in cells in different
phases of the cell cycle utilizing flow cytometry. The re-
sults are expressed as the percentage increase in volume
in stretched cells compared to non-stretched controls.
Figure 1A shows that compared to control (nonstretched)
podocytes grown in the presence of serum, stretch in-
creased cell volume in wild-type mouse podocytes in
G0/G1 at 24 hours (P < 0.05 vs. control) and 48 hours
(P < 0.05 vs. control), but not at 72 hours (P > 0.05
vs. control). Stretch also increased cell size in wild-type
podocytes in S phase (P < 0.01 vs. control), and in G2/M
phase (P < 0.01 vs. control) (Fig. 1B and C). Consistent
with our previous studies [17], stretch also caused a delay
in G1-phase progression in stretched podocytes grown in
serum (Table 1). The data shown are the mean of five
separate experiments.
We have previously shown that stretch increases the
levels of the CDK inhibitors p21 and p27 in podocytes.
To determine the role of p27 in mediating stretch-induced
hypertrophy, single p27−/− podocytes were exposed to
stretch. Figure 1 shows that compared to nonstretched
p27−/− podocytes, cell volume increased in stretched
single p27−/− podocytes in G0/G1, S, and G2/M phases,
and the increase was statistically significant at all time
points (P < 0.05 to P < 0.001 vs. nonstretched podocytes
at 24 hours, 48 hours, and 72 hours). Interestingly, in
podocytes lacking p27, the increase in cell size induced
by stretch was greater than in wild-type cells exposed to
stretch. The data shown is the mean of four separate ex-
periments.
We have previously reported that p21 levels also in-
creases in wild-type podocytes exposed to stretch. In or-
der to determine if p21 also increased in single p27−/−
podocytes, we performed Western blot analysis. Figure 2
shows that there was a moderate increase in the expres-
sion levels of p21 in stretched p27−/− podocytes. These
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Fig. 1. Stretch increases hypertrophy in wildtype podocytes, but not in
cells lacking the cyclin-dependent kinase (CDK) inhibitor p21. Cell
volume, a measure of hypertrophy, was measured by fluorescence-
activated cell sorter (FACS) analysis in cells in each phase of the cell cy-
cle. The results are expressed as the increase in cell volume of stretched
cells compared to nonstretched control cells. (A) Mechanical stretch
induces an increase in cell size in wild-type (WT) and p27 null (−/−)
podocytes in G0/G1 compared to control cells. In single p21−/− and
double p21/p27−/− podocytes, stretch did not induce hypertrophy in
cells in G0/G1. (B) In cells in S phase, stretch induced hypertrophy in
wild-type and single p27−/− podocytes, but not in single p21−/− and
double p21/p27−/− podocytes. (C) The effect of stretch on hypertrophy
was similar in cells in G2/M phase. ∗P < 0.05 vs. control nonstretched
podocytes; ∗∗P < 0.001 vs. control nonstretched podocytes; ∗∗∗P < 0.001
vs. control nonstretched podocytes.
results show that p27 alone is not required for stretch-
induced hypertrophy.
Single p21−/− podocytes were utilized to examine
the role of this CDK inhibitor in mediating hypertro-
phy induced by stretch. Figure 1 shows that in con-
trast to wild-type and single p27−/− podocytes, stretch
did not increase cell size in single p21−/− podocytes in
G0/G1, S, and G2/M phases at 24 hours, 48 hours, and
72 hours. Indeed, cell size decreased in stretched single
Table 1. Phases of the cell cycle in wild-type, p27−/−, p21−/−, and
double p21/p27−/− podocytes at baseline, in static control cell (C),
and stretched (S) cell at 24 hours
G0/G1 S G2
Wild-type
Baseline 83.9% ± 4.7% 6.3% ± 3.4% 9.8% ± 2.7%
C 24 hours 48.5% ± 7.8%a 38.7% ± 6.1%b 12.8% ± 1.9%
S 24 hours 63% ± 6.2%a 28.5% ± 6.6%b 8.5% ± 4.8%
p27−/−
Baseline 79.1% ± 2.7% 10.7% ± 3.2% 10.2% ± 1.8%
C 24 hours 47.9% ± 3%b 7.7% ± 1.7% 44.4% ± 1.3%a
S 24 hours 60.7% ± 2.6%b 12.3% ± 2.9% 27% ± 0.37%a
p21−/−
Baseline 42.8% ± 7.8% 25.7% ± 3% 31.5% ± 5.9%
C 24 hours 22.4% ± 4.4% 45.7% ± 9.1% 31.9% ± 5.8%
S 24 hours 23.6% ± 0.8% 44.8% ± 4.6% 31.6% ± 3.4%
Double p21/p27−/−
Baseline 46.1% ± 3.3% 23.2% ± 6.7% 30.7% ± 4.5%
C 24 hours 26% ± 7.2% 44.4% ± 6.1% 29.6% ± 3.9%
S 24 hours 27.8% ± 5.6% 45.9% ± 5.1% 26.3% ± 3.1%
aP < 0.001 stretched cells compared to control cells; bP < 0.01 stretched cells
compared to control cells.
p21−/− podocytes compared to nonstretched control sin-
gle p21−/− podocytes. In contrast to wild-type podocytes,
stretch did not arrest cells at G1/S in p21−/− podocytes
(Table 1) (P > 0.5 stretched cells compared to control
cells). The data shown are the mean of five separate ex-
periments. These results show that the presence of p21 is
required for stretch-induced hypertrophy.
We utilized double p21/p27−/− podocytes to deter-
mine if both CDK inhibitors were required for the hyper-
trophic effect of stretch. Figure 1 shows that stretch did
not induce hypertrophy in double p21/p27−/− podocytes
compared to control nonstretched cells in G0/G1, S, and
G2/M phases at 24 hours, 48 hours, and 72 hours (P >
0.05 vs. control at each time point). The data shown
is the mean of five separate experiments. Stretch did
not cause G1/S arrest in double p21/p27−/− podocytes
(Table 1) (P > 0.5 stretched cells compared to control
cells). These results show that (1) stretch induces hyper-
trophy in podocytes, and that this requires the presence
of the CDK inhibitor p21, but not p27; (2) stretch also re-
duces cell cycle progression in single p21−/− and double
p21/p27−/− podocytes, and (3) that hypertrophy requires
that cells arrest at G1/S.
Stretch-induced hypertrophy requires the presence
of mitogens
To determine if stretch-induced hypertrophy requires
the presence of serum (a source of growth factors) and cell
cycle entry we also measured hypertrophy in stretched
podocytes grown in the absence of mitogenic concen-
trations of serum [0.5% fetal calf serum (FCS)], which
is required to prevent apoptosis. Figure 3 shows that in
the absence of mitogenic concentrations of serum, stretch
does not induce hypertrophy in cells in G0/G1 and G2/M
phases at 24 hours and 48 hours. These results show that
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Fig. 2. p21 increases in stretched single
p27−/− podocytes. The upper panel shows
that the protein levels for p21 were measured
by Western blot analysis in single p27−/−
podocytes exposed to stretch. The lower panel
shows that the densitometric analysis was per-
formed using the housekeeping protein, tubu-
lin, and expressed in arbitrary units. The tubu-
lin blot is identical to the one presented in
Figure 5 (same protein isolation). Mechanical
stretch increased the levels of p21 compared
to control cells not exposed to stretch, and this
was maximal at 1 hour. The experiment was
performed twice.
cells must engage the cell cycle in order for stretch to
induce hypertrophy.
Mechanical stretch induces changes in the levels of Akt
and MAPKs
We have previously shown that stretch reduces
podocyte proliferation, and in the current study we now
show that stretch also induces hypertrophy. To determine
which signaling pathways mediate the effect of stretch on
podocyte growth, we measured Erk1/2 and Akt. Figures 4
and 5 show that stretch decreased the phosphorylated
form of Erk1/2 (Erk1/2 p) in podocytes grown in 5% FCS.
Compared to control nonstretched podocytes, this was ac-
companied by a decrease in the phosphorylated forms of
the Erk1/2 regulatory kinases, Raf and Mek (Fig. 4), and
also in p90RSK, a kinase downstream of Erk1/2 (Fig. 4).
We also measured the proproliferative kinase, Akt.
Stretch decreased the serine and threonine phosphory-
lated forms of Akt, which are the active forms of Akt
(Figs. 4 and 5) in podocytes grown in serum. In contrast to
the decrease in ERK and Akt, Figures 4 and 5 show that
stretched increased the levels of phosphorylated GSK-
3b kinase. This was accompanied by a marked increase
in phosphorylated p38 (Figs. 4 and 5). Finally, stretch did
not alter the levels of the H-, K-, and N-RAS isoforms
(results not shown).
Inhibiting Erk and Akt decreases
stretch-induced hypertrophy
Activation of Erk and Akt is necessary for cell cycle en-
try and progression through G1 phase. Figure 6A shows
cell cycle synchronization by starving in 0.5% serum for
48%. Figure 6B shows that when control (nonstretched)
wild-type podocytes are transfered into 5% serum, cells
enter the cell cycle. However, stretch significantly re-
duces cell cycle progression in cells grown in 5% serum
(Fig. 6C). To determine the role of Erk and Akt in
mediating hypertrophy induced by stretch, we exposed
podocytes to specific inhibitors. Figure 6D shows that
when stretch was applied to podocytes grown in serum
in the presence of LY294002, an inhibitor of PI3K an
upstream activator of Akt, cells did not engage cell cy-
cle. The binding of PI3K generated phospholipids to the
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Fig. 3. Stretch does not induce hypertrophy in quiescent wild-type
podocytes. Hypertrophy was measured by fluorescence-activated cell
sorter (FACS) analysis in cells grown in 0.5% serum, exposed to stretch,
and in control cells not exposed to stretch. Stretch did not induce a sta-
tistically significant increase in cell size in wild-type podocytes in G0/G1
phase, nor in G2/M, compared to nonstretched cells. P > 0.05 control
cells compared to stretch cells.
pleckstrin homology (PH) domain of Akt leads to the
translocation of Akt to the membrane and induces con-
formational changes that are required for proper phos-
phorylation and activation of Akt. As no specific inhibitor
of Akt is available an indirect blocking method by using
LY294002 was chosen. Similarly, exposing podocytes to
PD98059, the Erk1/2 inhibitor (Fig. 6E), also prevented
cell cycle entry. The cell cycle distribution and the total
cellular events measured are presented in Table 2.
To determine if inhibiting cell cycle entry prevented
stretch-induced hypertrophy, cell size was measured
in stretched cells exposed to Erk and Akt inhibitors.
Figure 6F shows that hypertrophy induced by stretch was
significantly reduced in cells in G0/G1. In contrast, inhibit-
ing Erk and Akt did not significantly alter cell size in cells
in G2/M. These results show that stretch did not induce
hypertrophy in cells that were unable to enter cell cycle,
and also shows that the effects of serum are mediated by
Erk1/2 and/or Akt for stretch-induced hypertrophy.
p38 has been shown to cause hypertrophy in cardiac
cells [19], and our results showed that p38 phosphoryla-
tion was increased in podocytes exposed to stretch (Figs. 4
and 5). In contrast to inhibiting Erk or Akt, our results
showed that inhibiting p38 did not affect stretch-induced
hypertrophy in podocytes (results not shown). More-
over, p38 phosphorylation coincided with an increase in
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Fig. 4. Differential expression of signaling
proteins in control nonstretched and stretched
podocytes grown in the presence of 5% serum.
Control (C) and stretched (S) podocytes were
grown in 5% serum, a source of growth fac-
tors. Stretch reduced the levels of active extra-
cellular signal-regulated kinase 1/2 (Erk1/2-
P), Raf (Raf-P), and mitogen-activated pro-
tein (MAP) kinase kinase (MEK) (MEK-P).
Stretch increased phosphorylated p38 (p38-P)
and GSK-3b (GSK-3b-P). In contrast, the in-
crease in the serine (Akt-PS) and threonine
(Akt-PT) phosphorylated forms of Akt in-
duced by serum in control cells was reduced
by stretch. The housekeeping protein, tubulin,
was used as a protein-loading control.
Erk-P
p38-P
Akt-P-S
Akt-P-T
GSK-P
Tubulin
C S C S C S C S
1h 6h 12h 24h
Fig. 5. Western blot analysis of protein iso-
late from control and stretched wild-type
podocytes at later time points. Mechanical
stretch reduced phosphorylated extracellular
signal-regulated kinase (Erk) and Akt (Akt-
PS, Akt-PT), and increased the phosphory-
lated levels of p38 (p38-P) and GSK-3b (GSK-
3b-P).
GSK-3b phosphorylation. Inhibiting p38 phosphoryla-
tion with SB203580 also decreased the phosphorylation
of GSK-3b (Fig. 7). These results show that p38 is up-
stream of GSK-3b , but inhibiting the phosphorylated
form that increases upon stretch, has no effect on hy-
pertrophy.
DISCUSSION
The growth response to podocyte injury is a critical de-
terminant in the course and prognosis of specific glomeru-
lar diseases. Typical podocyte growth responses to injury
include a lack of proliferation and an increase in cell size
due to hypertrophy. However, the mechanisms governing
podocyte growth in states of increased intraglomerular
pressure, including diabetic nephropathy, are not known.
Our results show that stress-tension induced by mechan-
ical stretch induces podocyte hypertrophy, and this re-
quires the CDK inhibitor p21, and the signal proteins
Erk1/2 and Akt.
Increased intraglomerular pressure characterizes pro-
gressive glomerulopathies, and studies have shown that
normalizing intraglomerular pressure reduces progres-
sive glomerulosclerosis [20]. Although podocytes are
injured by increased intraglomerular pressure, little is
known about the mechanisms underlying this effect. In an
attempt to simulate these events in vitro, cultured mouse
podocytes were exposed to stretch as we [17] and others
[21] have described, similar to what other investigators
have done for mesangial [22] and vascular smooth mus-
cle cells [23].
The first major finding in this study was that stretch
induced hypertrophy in podocytes in culture. This oc-
curred only when podocytes were grown in the pres-
ence of serum, used as a source of growth factors, and
not in quiescent (serum-free) podocytes. Inhibiting entry
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Fig. 6. Extracellular signal-regulated kinase (Erk) and Akt are required for cell cycle progression. Phases of the cell cycle were measured by
fluorescence-activated cell sorter (FACS) analysis. (A) Wild-type podocytes are grown in 0.5% serum synchronized growth-arrested cells. (B)
Growing nonstretched control podocytes in 5% serum caused cycle entry and progression. (C) Stretch reduced cell cycle progression. (D) The
addition of Ly294002, an inhibitor of Akt, to podocytes grown in serum, prevented cell cycle entry. (E) PD98059, an Erk inhibitor, prevented
entrance into the cell cycle. (F) When grown in 5% serum and exposed to stretch, Akt and Erk inhibitors reduced stretch-induced hypertrophy in
cells in G0/G1, but had no major effect on cells in G2/M. ∗∗P < 0.01 inhibitor-treated cells compared to untreated cells; ∗P < 0.05 inhibitor-treated
cells compared to untreated cells.
Table 2. Cell cycle distribution of the data presented in Figure 6.
D0 + DMSO C 24 hours + DMSO S 24 hours + DMSO S 24 hours + DMSO + LY294002 S 24 hours + DMSO + PD98059
G0/G1 66.9% 23.8% 36.6% 62.8%a 52.1%a
S 14.4% 59.7% 48.7% 13.6%a 22.1%a
G2/M 18.7% 16.5% 14.7% 23.6% 25.8%
Total events 2210 9703 2919 1822 1618
DMSO is dimethylsulfoxide.
This experiment was performed a total of three times.
aP < 0.01 compared to S 24 hours + DMSO.
into cell cycle by suppressing the proproliferative kinases,
Erk1/2 and Akt, abolished stretch-induced hypertrophy.
Thus, cell cycle entry is required for hypertrophy. Our
results also showed that the effects of stretch on hyper-
trophy were not limited to cells in a specific phase of cell
cycle, because cell size increased in podocytes that were
in G0/G1, S, and G2/M phases. Previous studies have also
shown that stretch induces hypertrophy in skeletal mus-
cle cells and cardiac myocytes [24, 25]. In this study, we
assessed hypertrophy by measuring changes in cell size
by fluorescence-activated cell sorter (FACS) analysis, be-
cause we and others have shown that FACS analysis is
a very sensitive and specific method for measuring cell
hypertrophy [26, 27]. Moreover, a major advantage of
FACS over other measures of hypertrophy such as pro-
tein:DNA ratios, is the ability to measure hypertrophy
in each phase of the cell cycle. Endlich et al [21] had
originally described a decrease in cell size by mechan-
ical stretch. They were looking for changes in the area
of the cell body by estimating the product of cell body
width and length. The definition of hypertrophy is an in-
crease in cell size/volume/protein. As the cell is a three-
dimensional structure, the product of body width and
length neglects the third important parameter (i.e., cell
height). For this reason FACS might be a more sensi-
tive approach for looking for changes in cell size than
morphometry. Preliminary data in mesangial cells (not
shown) also showed that protein:DNA measurements,
and the results obtained by FACS, were similar. We there-
fore have reported our FACS data.
We and others have recently shown a role for the CDK-
inhibitors p21 and p27 in renal cell growth [26, 28, 29]. A
second major finding in this study was that cell size did
not increase in single p21−/− and double p21/p27−/−
podocytes exposed to stretch. In contrast, hypertrophy
was detected in wild-type and single p27−/− podocytes
exposed to stretch. We also asked if the induction of hy-
pertrophy by stretch required cell cycle arrest. Our re-
sults showed that stretch delayed cell cycle progression
in wild-type and single p27−/− podocytes grown in serum
(a source of mitogens). However, stretch did not arrest
p21−/− and double p21/p27−/− cells exposed to serum.
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Fig. 7. Inhibiting p38 reduced GSK-3b phosphorylation. Stretch (S)
(lane 2) increased phospho-p38 compared to control cells (C) (lane 1).
The increase coincided with an increase in GSK-b . Lane 3 shows that
inhibiting p38 with SB203580 reduced the levels of phosphorylated p38
and GSK-3b in stretched cells.
Taken together, these results show that p21 is required
for stretch-induced hypertrophy in podocytes, and that
hypertrophy only occurs in cells that enter the cell cy-
cle, but are capable of arresting. Furthermore, cell cy-
cle arrest and hypertrophy requires the presence of the
CDK inhibitor p21. The antiproliferative effect of stretch
on podocytes differs from the proproliferative effect of
stretch on mesangial and vascular smooth muscle cells
[22, 23]. Surprisingly, cell types lacking p21 showed a ten-
dency to cell size decrease by stretch. The reason for this
is unclear. As our data show no difference in cell cycle
progression between control and stretched cells we can-
not argue that the presence of p27 pushes cells in the cell
cycle and therefore reduces cell size. One could only spec-
ulate that the lack of p21 makes a cell more vulnerable
to stretch and therefore induces cell size decrease.
A role for specific CDK inhibitors has been shown in re-
nal growth. p21 is necessary for glomerular hypertrophy
accompanying experimental diabetic nephropathy [30]
and glomerular hypertension [28]. Overexpressing p21
induces tubular cell hypertrophy [31], and the upregula-
tion of p21 by heme oxygenase-1 underlies hypertrophy
in LLC-PK1 cells [32]. Interestingly, our study showed
that p21 levels increased early in p27−/− podocytes ex-
posed to stretch, and was therefore likely sufficient to
overcome the loss of p27. The CDK inhibitor p27 is also
a critical determinant of mesangial cell hypertrophy in-
duced by hyperglycemia, and overexpressing p27 alone is
sufficient to induce renal cell hypertrophy [29]. A role for
p27 in angiotensin II–mediated hypertrophy of proximal
tubular cells [33] and vascular smooth muscle cells [34]
has also been reported. Finally, we have recently shown
that both p21 and p27 are required for maximal mesan-
gial cell hypertrophy induced by TGF-b [35]. However,
the results of the current study show that both CDK in-
hibitors are not required for maximal stretch-induced hy-
pertrophy, because cell size was similar in p21−/− and
double p21/p27−/− podocytes exposed to stretch. Taken
together, the results of the current study indicate that the
role of specific CDK inhibitors in hypertrophy may be
dependent on the cell type, and also on the type of injury.
Specific signaling pathways govern proliferation in re-
sponse to extracellular cues, which in turn modulate spe-
cific cell cycle regulatory proteins [13, 14]. Erk1/2 has
been shown to increase cyclin D1 transcription and to
modify other cell cycle proteins [36]. This contrasts to the
Erk1/2 in mesangial cells exposed to stretch [37]. A third
finding in the current was that stretch significantly re-
duced the Erk1/2 pathway in podocytes grown in the pres-
ence of mitogens (serum). Our results also showed that
stretch decreased the active forms of Raf and Mek1/2, ac-
tivators of Erk1/2. Similarly, stretch also decreased phos-
phorylated p90RSK, which is downstream of Erk1/2.
Akt is a potent proproliferative signaling protein, and
induces proliferation by increasing cyclin D1 transcrip-
tion and translation [37, 38] and by inhibiting the CDK
inhibitors p21 and p27 [39, 40]. Our results showed that as
expected, Akt was increased in control podocytes grown
in serum, not exposed to stretch. However, stretch signifi-
cantly reduced both forms of phosphorylated (and active)
Akt.
The decrease in Erk and Akt levels suggested a po-
tential role for these pathways in mediating the effects
of stretch on podocyte growth. Thus, to demonstrate the
role of Erk and Akt in stretch-induced hypertrophy, we
inhibited these pathways pharmacologically in podocytes
grown in serum, prior to the application of stretch. These
kinase inhibitors have been described in the literature as
highly specific at the concentrations used in our studies
[41]. Of course, crossreactions with other, possibly un-
known, kinases can not be excluded. For the selection
of the inhibitor concentrations we used several different
approaches. First, we contacted the providers for recom-
mendation. Second, we studied the literature for used
concentrations in different cell lines [41]. Third, we per-
formed some pilot experiments in our laboratory using
kinase inhibitors at different concentrations in mesangial
cells. Our results showed that by inhibiting Erk and Akt,
the hypertrophic effects of stretch in wild-type and single
p27−/− podocytes were abolished. These results show
that Erk and Akt have a role in stretch-induced hyper-
trophy in podocytes.
We also studied p38 MAPK in stretched podocytes
because this pathway is increased in response to cer-
tain cell stressors and has been shown to cause hyper-
trophy in cardiac myocytes [19]. Our results showed that
stretch caused a marked increase in p38 phosphorylation.
However, inhibiting p38 with different concentrations of
SB203580 had no effect on podocyte hypertrophy or pro-
liferation. Thus, the functional role of increased p38 in
stretched podocytes remains to be determined.
Although GSK-3b was initially thought to be restricted
to glycogen metabolism, studies have shown that it is also
a critical signaling protein. Activation by dephosphory-
lation induces apoptosis. A recent study also showed that
inactivation of GSK-3b by phosphorylation is required
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for cardiomyocytes to undergo hypertrophy [42]. GSK-
3b is negatively regulated by phosphorylation by Akt
[43]. Thus, by phosphorylating and inhibiting GSK-3b ,
Akt also increases cell number by inhibiting apopto-
sis [44]. Although we anticipated that the decrease in
Akt caused by stretch would lead to activation (dephos-
phorylation) of GSK-3b , our results showed that stretch
increased GSK3-b phosphorylation, and therefore inac-
tivation. However, our results showed that inhibiting p38
decreased GSK-3b phosphorylation, suggesting that p38
might regulate GSK-3b in stretched podocytes. More-
over, the lack of podocyte apoptosis in stretched cells
may be due to GSK-3b inactivation.
CONCLUSION
We show that mechanical stretch induces hypertrophy
in cultured podocytes. This requires entry into cell cycle,
and is dependent on the presence of the CDK inhibitor
p21, but not p27. These data provide a potential mecha-
nism for the increase in podocyte size in diseases associ-
ated with increased intraglomerular pressure.
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